avalglucosidase alfa-ngpt (Nexviazyme)
Jump to navigation
Jump to search
Indications
- enzyme replacement therapy for Pompe disease
* avalglucosidase alfa-ngpt (Nexviazyme) indicated for late-onset disease >= 1 year of age (FDA-approved)
* alglucosidase alfa (Lumizyme) indicated for patients >= 8 years of age
Dosage
- IV infusion every 2 weeks
Adverse effects
- hypersensitivity reactions including anaphylaxis
- infusion-associated reactions
- arthralgia, nausea, vomiting, diarrhea
- headache, myalgia, paresthesia, dizziness, fatigue
- erythema, pruritus, urticaria
- persons susceptible to fluid volume overload or with compromised cardiac or respiratory function may be at risk for serious acute cardiorespiratory failure
Mechanism of action
- target the mannose-6-phosphate (M6P) receptor
More general terms
References
- ↑ Ingram I New Enzyme Therapy OK'd for Pompe Disease. IV treatment improved lung function, 6-minute walk test in later-onset disease. MedPage Today August 6, 2021 https://www.medpagetoday.com/publichealthpolicy/fdageneral/93944
- ↑ Brooks M FDA Clears New Enzyme Replacement Therapy for Pompe Disease Medscape - Aug 06, 2021. https://www.medscape.com/viewarticle/956179
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION LUMIZYME (alglucosidase alfa). for injection, for intravenous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125291lbl.pdf